Skip to main content
. 2017 Sep 7;37(5):BSR20170696. doi: 10.1042/BSR20170696

Figure 4. XIST/miR-29c axis regulated glioma cell chemoresistance to TMZ through DNA mismatch repair (MMR) pathway.

Figure 4

U251/TMZ and LV229/TMZ cells were cotransfected with si-XIST and miR-29c inhibitor. (A,B) The cell viability and DNA synthesis capability were determined using MTT and BrdU assays. (C,D) Twenty four hours after transfection, cells were treated with a series dose of TMZ (7.5, 15, 30, 60, 120, 240, and 480 μM) for 24 h; the cell viability was then determined using MTT assays. Data were displayed as described. (E) The protein levels of MSH6 were determined using Western blot assays. (F) The protein levels of SP1 and MGMT were determined using Western blot assays. The data are presented as mean ± S.D. of three independent experiments; *P<0.05, **P<0.01. #P<0.05, ##P<0.01, compared to si-XIST + inhibitor-NC group.